ONO-7702 will be administered orally once daily in combination with ONO-7703 twice daily.

2 trials

Sponsors

Hirashima Yoshinori

Conditions

Radically unresectable BRAF V600-mutant thyroid cancer

Phase 2

ONO-7702/7703-03:NO-7702/ONO-7703 Phase2 Study

Active, not recruitingJPRN-jRCT2011200018

Hirashima YoshinoriRadically unresectable BRAF V600-mutant thyroid cancer

Start: 2021-03-26Target: 19Updated: 2026-06-29

Expanded Access Program of ONO-7702/ONO-7703 (ONO-7702/7703-03E)

Active, not recruitingJPRN-jRCT2011230032

Hirashima YoshinoriRadically unresectable BRAF V600-mutant thyroid cancer

Start: 2024-01-10Target: 20Updated: 2026-06-29

Related Papers

A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary

Figshare2026-03-16

A study to learn how well the combination of encorafenib and binimetinib works and how safe it is in adults with thyroid cancer: a plain language summary

Figshare2026-03-16

A Phase 2 Study of Encorafenib in Combination with Binimetinib in Patients with Metastatic <i>BRAF</i> -Mutated Thyroid Cancer in Japan

Thyroid2024-02-1216 citations